Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 1039-1042

  Wasif Saif, M ^a  

^a Milstein Hospital ^*  (United States)

Author keywords

Cetuximab; Chemoresistance; Chemosensitivity; Chemotherapy; Erlotinib; Pancreatic neoplasm

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; FEMALE; HEALTH INSURANCE; HUMAN; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; SENSORY NEUROPATHY; SINGLE DRUG DOSE; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES;

EID: 79956094173     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Saif MW: Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006. JOP. J Pancreas (Online) 7: 337-348, 2006.
3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
5. Rusch V, Mendelsohn J and Dmitrovsky E: The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 7: 133-141, 1996. (Pubitemid 27198072)
6. Davies DE and Chamberlin SG: Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 51: 1101-1110, 1996. (Pubitemid 26127887)
7. Baselga J and Mendelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29: 127-138, 1994. (Pubitemid 24104844)
8. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J and Lawrence TS: The combination of EGFR inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res. 14(16): 5142-5149, 2008.
9. Solorzano CC, Baker CH, Tsan R et al: Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 7(8): 2563-2572, 2001. (Pubitemid 32751663)
10. Furugaki K, Iwai T, Kondoh K, Moriya Y and Mori K: Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncol Lett 1(2): 231-235, 2010.
11. Mitchell EP, Perez-Soler R, Van Cutsem E and Lacouture ME: Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park) 21(11 Suppl 5): 4-9, 2007.
12. Gerdes S and Mrowietz U: Follicular rash during therapy with erlotinib (Tarceva). J Dtsch Dermatol Ges 4: 855-857, 2006. (Pubitemid 44434329)
13. Boeck S, Hausmann A, Reibke R, Schulz C and Heinemann V: Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 18: 1109-1111, 2007.
14. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345, 2004. (Pubitemid 38944402)
15. James E, Waldron-Lynch MG and Saif MW: Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.Anticancer Drugs 20(7): 634-638, 2009.
16. Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N and Nishio K: Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98(2): 310-315, 2002. (Pubitemid 34150818)
17. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB and Chiao PJ: Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 7(7): 37-43, 2003. (Pubitemid 36875799)
18. Bandyopadhyay D, Mandai M, Adam L, Mendelsohn J and Kumar R: Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273(3): 1568-1573, 1998. (Pubitemid 28133681)
19. Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaneret I et al: Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone in second-line therapy of gemcitabine- refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 3(16 Suppl): 4031, 2005.
20. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M et al: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26(15 Suppl): 4508, 2008.
21. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E et al: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94: 481-485, 2006. (Pubitemid 43289750)
22. Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP and Bekaii-Saab TS: Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology 76: 333-337, 2009.
23. Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C et al: Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 67: 93-97, 2004. (Pubitemid 39482675)
24. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH et al: A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101: 1658-1663, 2009.
25. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL and Wolff RA: Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113: 2046-2052, 2008.
26. Oettle H, Arnold D, Esser M, Huhn D and Riess H: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11: 635-638, 2000.